Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,967 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk stratification and prognostic factors in patients with unresectable undifferentiated carcinoma of the pancreas.
Imaoka H, Ikeda M, Maehara K, Umemoto K, Ozaka M, Kobayashi S, Terashima T, Inoue H, Sakaguchi C, Tsuji K, Shioji K, Okamura K, Tsujimoto A, Nakamura I, Shirakawa H, Furukawa M, Ueno M, Morizane C, Furuse J. Imaoka H, et al. Among authors: ueno m. Pancreatology. 2021 Jun;21(4):738-745. doi: 10.1016/j.pan.2021.02.008. Epub 2021 Feb 14. Pancreatology. 2021. PMID: 33602645
Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients.
Morizane C, Okusaka T, Ueno H, Kondo S, Ikeda M, Furuse J, Shinichi O, Nakachi K, Mitsunaga S, Kojima Y, Suzuki E, Ueno M, Yamaguchi T. Morizane C, et al. Among authors: ueno h, ueno m. Cancer Chemother Pharmacol. 2012 Apr;69(4):957-64. doi: 10.1007/s00280-011-1786-6. Epub 2011 Nov 26. Cancer Chemother Pharmacol. 2012. PMID: 22120961 Clinical Trial.
Lack of associations between genetic polymorphisms in GSTM1, GSTT1 and GSTP1 and pancreatic cancer risk: a multi-institutional case-control study in Japan.
Yamada I, Matsuyama M, Ozaka M, Inoue D, Muramatsu Y, Ishii H, Junko U, Ueno M, Egawa N, Nakao H, Mori M, Matsuo K, Nishiyama T, Ohkawa S, Hosono S, Wakai K, Nakamura K, Tamakoshi A, Kuruma S, Nojima M, Takahashi M, Shimada K, Yagyu K, Kikuchi S, Lin Y. Yamada I, et al. Among authors: ueno m. Asian Pac J Cancer Prev. 2014;15(1):391-5. doi: 10.7314/apjcp.2014.15.1.391. Asian Pac J Cancer Prev. 2014. PMID: 24528063 Free article.
Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer.
Aoyama T, Katayama Y, Murakawa M, Asari M, Kanazawa A, Higuchi A, Shiozawa M, Kobayashi S, Ueno M, Morimoto M, Ohkawa S, Akaike M, Yamamoto N, Yoshikawa T, Rino Y, Masuda M, Morinaga S. Aoyama T, et al. Among authors: ueno m. Cancer Chemother Pharmacol. 2014 Dec;74(6):1235-40. doi: 10.1007/s00280-014-2601-y. Epub 2014 Oct 9. Cancer Chemother Pharmacol. 2014. PMID: 25297990
2,967 results